A. Ferry, J. Stemper, A. Marinetti, A. Voituriez, X. Guinchard
FULL PAPER
NMR (300 MHz, CDCl3): δ = 7.38–7.19 (m, 13 H, Har), 7.13–7.05 J = 11.1 Hz, 1 H, CH2Ph), 4.63 (d, J = 12.8 Hz, 1 H, CH2Ph), 4.53
(m, 2 H, Har), 5.61 (dd, J = 10.0 and 2.8 Hz, 1 H, 2-H), 4.80 (d, J (d, J = 12.4 Hz, 1 H, CH2Ph), 4.40 (d, J = 10.5 Hz, 1 H, CH2Ph),
= 11.1 Hz, 1 H, CH2Ph), 4.77 (d, J = 10.5 Hz, 1 H, CH2Ph), 4.70 4.30–4.20 (m, 1 H, 5-H), 3.96 (td, J = 10.0 and 2.4 Hz, 1 H, 3-H),
(d, J = 11.1 Hz, 1 H, CH2Ph), 4.64 (d, J = 12.1 Hz, 1 H, CH2Ph), 3.76–3.65 (m, 2 H, 4-H and 6-H), 3.64–3.55 (m, 1 H, 6-H), 1.14 (s,
4.55 (d, J = 10.5 Hz, 1 H, CH2Ph), 4.54 (d, J = 12.1 Hz, 1 H,
CH2Ph), 4.24–4.16 (m, 1 H, 5-H), 4.04–3.90 (m, 2 H, 3-H and 4-
H), 3.87–3.80 (m, 1 H, 6-H), 3.85 (d, J = 13.4 Hz, 3 H, OMe), 3.76
(dd, J = 11.1 and 1.3 Hz, 1 H, 6-H), 1.22 (s, 9 H, Piv) ppm. 13C
9 H, Piv) ppm. 13C NMR (75 MHz, CDCl3): δ = 177.0 (d, J =
3.3 Hz, Cq, C=O Piv), 137.9 (Cq, Car), 137.3 (Cq, Car), 137.0 (Cq,
Car), 128.7 (2 CH, Car), 128.7 (2 CH, Car), 128.6 (2 CH, Car), 128.4
(2 CH, Car), 128.4 (2 CH, Car), 128.3 (CH, Car), 128.3 (CH, Car),
NMR (75 MHz, CDCl3): δ = 176.5 (d, J = 3.8 Hz, Cq, C=O Piv), 127.9 (CH, Car), 127.4 (2 CH, Car), 82.2 (d, J = 4.9 Hz, CH, C-3),
137.9 (Cq, Car), 137.8 (Cq, Car), 137.7 (Cq, Car), 128.6 (3 CH, Car), 78.2 (CH, C-4), 77.4 (d, J = 8.8 Hz, CH, C-5), 76.0 (CH2Ph), 75.9
128.6 (2 CH, Car), 128.1 (4 CH, Car), 128.1 (2 CH, Car), 128.0 (CH, (CH2Ph), 73.8 (CH2Ph), 73.0 (d, J = 112.5 Hz, CH, C-2), 69.1 (d,
Car), 127.9 (CH, Car), 127.3 (2 CH, Car), 82.2 (d, J = 4.9 Hz, CH, J = 9.9 Hz, CH2, C-6), 39.1 (Cq, Piv), 27.3 (3 CH3, Piv) ppm.
C-3), 78.0 (d, J = 8.8 Hz, CH, C-5), 77.9 (CH, C-4), 76.0 (CH2Ph),
75.8 (CH2Ph), 73.8 (CH2Ph), 73.3 (d, J = 113.6 Hz, CH, C-2), 68.8
31P{1H} NMR (122 MHz, CDCl3): δ = 74.3 ppm. HRMS (ESI-
TOF): calcd. for C31H41NO7PS [M + NH4]+ 602.2341; found
(d, J = 9.9 Hz, CH2, C-6), 53.9 (d, J = 6.6 Hz, CH3, OMe), 39.1 602.2324.
(Cq, Piv), 27.3 (3 CH3, Piv) ppm. 31P{1H} NMR (122 MHz,
General Procedure for the Asymmetric Hydrogenation of 2-Phenyl-
CDCl3): δ = 80.7 ppm. HRMS (ESI-TOF): calcd. for C32H40O7PS
quinoline: A solution of 2-phenylquinoline (20.5 mg, 0.1 mmol),
Hantzsch ester (0.24 mmol, 2.4 equiv.), and the catalyst
(0.01 mmol, 10 mol-%) in toluene (2 mL) was stirred at room temp.
for 90 min. The solvent was evaporated in vacuo, and the residue
was purified on silica gel (eluent: toluene). 2-Phenyl-1,2,3,4-tetra-
[M + H]+ 599.2232; found 599.2261.
General Procedure for the Demethylation of Thiophosphonate Esters
to Thiophosphonic Acids: To a solution of thiophostone in toluene
was added Me3N at –78 °C. The resulting mixture was stirred at
50 °C for 3 h. The mixture was cooled to room temp. and the reac-
tion quenched with 1 n aqueous HCl. The two layers were sepa-
rated, and the aqueous layer was reextracted twice with EtOAc.
The combined organic layers were dried with MgSO4, filtered, and
concentrated to yield the pure thiophosphonic acid.
hydroquinoline was obtained as
a
colorless oil. 1H NMR
(500 MHz, CDCl3): δ = 7.45–7.34 (m, 4 H), 7.31 (t, J = 7.5 Hz, 1
H), 7.07–6.98 (m, 2 H), 6.68 (t, J = 7.5 Hz, 1 H), 6.57 (d, J =
8.0 Hz, 1 H), 4.46 (dd, J = 9.5, 3.3 Hz, 1 H), 4.10 (br. s, 1 H), 3.00–
2.88 (m, 1 H), 2.80–2.70 (m, 1 H), 2.21–2.10 (m, 1 H), 2.08–1.95
(m, 1 H) ppm. Chiral HPLC analysis: [CHIRALPAK® IB, 30 °C,
5% iPrOH/n-heptane, 1 mL/min, 250 nm, retention times: 6.8 min
(minor) and 8.6 min (major)]. [α]2D0 = +23 (c = 1.8, CHCl3; 68%
ee) {lit.: [α]2D0 = –37.7 (c = 1.1, CHCl3) for (S)-2-phenyl-1,2,3,4-
tetrahydroquinoline (97% ee),[19b] [α]2D0 = –34.8 (c = 1.1, CHCl3)
for (S)-2-phenyl-1,2,3,4-tetrahydroquinoline (96% ee)]}.[7a]
(2S,3S,4S,5S,6R)-4,5-Bis(benzyloxy)-6-[(benzyloxy)methyl]-2-
hydroxy-2-sulfido-1,2-oxaphosphinan-3-yl Pivalate (5f): Compound
5f was synthesized according to the general procedure by reaction
of 1f (25 mg, 0.042 mmol) in toluene (0.5 mL) and trimethylamine
(0.5 mL). Compound 5f was obtained as a colorless oil (22 mg,
0.038 mmol, 90%). [α]2D3 = +70.2 (c = 0.7, CHCl ). IR (neat): ν
˜
3
max
Supporting Information (see footnote on the first page of this arti-
= 2969, 2922, 2873, 1736, 1497, 1480, 1455, 1363, 1277, 1142, 1058,
989, 829, 742, 699 cm–1. 1H NMR (500 MHz, CDCl3): δ = 7.28–
7.15 (m, 13 H, Har), 7.07–7.00 (m, 2 H, Har), 4.91 (dd, J = 9.8 and
7.6 Hz, 1 H, 2-H), 4.75 (s, 2 H, CH2Ph), 4.72 (d, J = 11.0 Hz, 1 H,
CH2Ph), 4.56 (d, J = 12.0 Hz, 1 H, CH2Ph), 4.48 (d, J = 11.0 Hz,
1 H, CH2Ph), 4.43 (d, J = 12.0 Hz, 1 H, CH2Ph), 4.32–4.16 (br. s,
1 H, OH), 4.29–4.22 (m, 1 H, 5-H), 4.02 (td, J = 9.8 and 2.5 Hz,
1 H, 3-H), 3.85 (t, J = 9.8 Hz, 1 H, 4-H), 3.79 (dt, J = 11.0 and
2.5 Hz, 1 H, 6-H), 3.70 (dd, J = 11.0 and 1.3 Hz, 1 H, 6-H), 1.18
(s, 9 H, Piv) ppm. 13C NMR (125 MHz, CDCl3): δ = 179.8 (d, J =
1.8 Hz, Cq, Piv), 138.1 (Cq, Car), 137.9 (Cq, Car), 137.6 (Cq, Car),
128.7 (2 CH, Car), 128.6 (2 CH, Car), 128.6 (2 CH, Car), 128.2 (2
CH, Car), 128.2 (CH, Car), 128.1 (CH, Car), 128.0 (CH, Car), 127.9
(2 CH, Car), 127.6 (2 CH, Car), 82.3 (d, J = 10.1 Hz, CH, C-3),
77.6 (CH, C-4), 76.4 (CH2Ph), 76.1 (d, J = 98.1 Hz, CH, C-2), 75.6
(CH2Ph), 75.4 (d, J = 1.8 Hz, CH, C-5), 73.8 (CH2Ph), 68.4 (d, J
= 11.0 Hz, CH2, C-6), 39.1 (Cq, Piv), 27.4 (3 CH3, Piv) ppm.
31P{1H} NMR (202 MHz, CDCl3): δ = 82.7 ppm. HRMS (ESI-
TOF): calcd. for C31H36O7PS [M – H]– 583.1919; found 583.1926.
cle): Full experimental details and copies of 1H and 13C NMR spec-
tra.
Acknowledgments
A. F. thanks the Institut de Chimie des Substances Naturelles
(ICSN) for a fellowship; J. S. thanks the Ministère de l’Enseigne-
ment Supérieur et de la Recherche (MESR) and the Paris-Sud Uni-
versity for a fellowship. This work was also support by the Agence
Nationale de la Recherche (ANR Blanc, “Chiracid”) and the
COST ORCA action CM0905.
[1] A. G. Doyle, E. N. Jacobsen, Chem. Rev. 2007, 107, 5713.
[2] a) T. Akiyama, Chem. Rev. 2007, 107, 5744; b) M. Terada,
Chem. Commun. 2008, 4097; c) M. Terada, Synthesis 2010,
1929.
[3] a) T. Akiyama, J. Itoh, K. Yokota, K. Fuchibe, Angew. Chem.
2004, 116, 1592; Angew. Chem. Int. Ed. 2004, 43, 1566; b) D.
Uraguchi, M. Terada, J. Am. Chem. Soc. 2004, 126, 5356; c) J.
Seayad, A. M. Seayad, B. List, J. Am. Chem. Soc. 2006, 128,
1086.
(2R,3S,4S,5S,6R)-4,5-Bis(benzyloxy)-6-[(benzyloxy)methyl]-2-
hydroxy-2-sulfido-1,2-oxaphosphinan-3-yl Pivalate (7f): Compound
7f was synthesized according to the general procedure by the reac-
tion of 3f (95 mg, 0.159 mmol), toluene (3 mL), and trimethylamine
(1 mL). Compound 7f was obtained as a colorless oil (82.7 mg,
[4] G. B. Rowland, H. Zhang, E. B. Rowland, S. Chennamad-
havuni, Y. Wang, J. C. Antilla, J. Am. Chem. Soc. 2005, 127,
15696.
0.142 mmol, 89%). [α]2D3 = +54.7 (c = 0.2, CHCl ). IR (neat): ν
˜
3
max
[5] a) T. Akiyama, Y. Saitoh, H. Morita, K. Fuchibe, Adv. Synth.
Catal. 2005, 347, 1523; b) A. Voituriez, A. B. Charette, Adv.
Synth. Catal. 2006, 348, 2363.
= 3031, 2970, 2931, 2871, 1744, 1454, 1363, 1274, 1125, 1091, 1048,
1027, 964, 736, 717, 696 cm–1. 1H NMR (300 MHz, CDCl3): δ =
7.30–7.11 (m, 13 H, Har), 7.00–6.93 (m, 2 H, Har), 5.94–5.70 (br. s,
1 H, OH), 5.47 (dd, J = 10.4 and 3.2 Hz, 1 H, 2-H), 4.71 (d, J =
11.3 Hz, 1 H, CH2Ph), 4.66 (d, J = 10.9 Hz, 1 H, CH2Ph), 4.64 (d,
[6] a) F. Xu, D. Huang, C. Han, W. Shen, X. Lin, Y. Wang, J. Org.
ˇ
Chem. 2010, 75, 8677; b) I. Coric´, S. Müller, B. List, J. Am.
Chem. Soc. 2010, 132, 17370.
192
www.eurjoc.org
© 2014 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim
Eur. J. Org. Chem. 2014, 188–193